Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great news, even Primary Dr.s can use it before a dermatolgist Dr. Visit. Huge revenues coming.
DMTK
IMO, too many people were in this early for the CMS approval pop; sell the news now in progress
Looks like an Institutional buyer tying to keep in 12.00 range while they load more before running this up over 20.00 soon. We should see the delayed PR this week. GLTA
DMTK
not sure either; I think 'everyone' (including myself) thought the CMS approval was going to gap us up 50%+ and thus far crickets. 'Maybe' it was already priced in as a sure thing(?) 'Maybe' the pr will help(?)
I haven't sold any and am waiting for a big move at some point(??)
g/l!!
This is big news , not sure why the delay on a PR.
DMTK
not the reaction I expected either BUT am also in it for the med-long term
g/l!!
$DMTK guess I’m marginally surprised they haven’t PR’d this yet. No matter great news for the long holder like myself. GLTA!
fingers crossed! getting antsy here LOL
Thanks db7, AH ;]
DMTK
Hi greens, I do not know the exact time it is published BUT I did some research into EXAS and it's CMS LCD approval and judging by the trading action it appears the approval was posted after hours(?)
Look at what EXAS did on it's CMS LCD Approval:
10/09/2014 closed at $18.12 on 980,892 shares traded
* CMS LCD approval on 10/9 *
10/10/2014 gapped up and hit a high of $26.79 on 17,259,562 shares traded
Good morning db7, looks like news comes next thurs. unless CMS releases news sometime later today ?
DMTK
It's so thin I think the moves will be dramatic up and down; 'I think' we will get at least a 50% move up on the day of the CMS LCD approval (assuming we do get approval)… !ONLY 'MY' OPINION! EXAS moved about 50% when it got it's LCD approval and we are much thinner..etc...etc..
Thanks for the info....do you think there will be any shorts trying to manipulate this low float ?....The way i see it is if they did they would be completely ignoring the awesome fundamentals and earnings potential in the near future .
DMTK
Hi greens, i mentioned cms lcd approvals seem to all get published on Thursday's. Not sure if this Thur or the next or a Thur month(s) from now. I haven't sold any warrants, actually added a tiny bit more
G/L!!
hello db7, do you still expect news on Thursday ? Added more shares and warrants today on the dip. With 300.00 savings cost Vs. Biopsy this dmtk skin Patch will become a SOC with Medicare and expect huge revenues.
DMTK
she is just so thin; I think we're going to do very well with DMTK and DMTKW as long as we get that approval
This is truly looking like it could see $25+ on approval imo
BUT as I mentioned before what i'm really hoping for is an insane, parabolic move... aka to like $40+
time will tell....
g/l!!
Agreed. 'Hoping' it goes on a crazy, low-float multi-day run. Not sure if you saw it and it's definitely not apples to apples but a few weeks back krtx went from like $18 to $150. An epic run like that here would be much appreciated lol
$DMTK Medicare approval = $20.00 plus IMHO.
Great day db7, I think now that it is over 10.00 it will move faster. CMS news ...tick tock
DMTK
beautiful day, sooo thin!
Warrants haven't even begun imho. I'm hoping for $2+ out of them. Time will tell-
Thanks for sharing that Tall! $15 seems extremely conservative imo. Could hit that in a few days of volume w/o news IMO
Hoping for $20+ day of or after Medicare approval (assuming it's granted etc)
G/L!!
The float is getting locked up, not much left for retail......I was watching the warrants sky rocket today congrats to you. Medicare news will be explosive as more people find out about the revenues coming .
DMTK
Lake Street Capital Markets Analyst Thomas Flaten initiated coverage of DermTech, Inc. with a BUY rating and price target of $15 (DMTK $7.60).
DermTech is a molecular diagnostics company developing and marketing novel gene expression-based tests for various dermatologic applications, including the Pigmented Lesion Assay for the diagnosis of melanoma. Combining gene expression assays with the Company’s adhesive patch technology allows for non-invasive testing. In addition to advancing a proprietary pipeline of diagnostic tests, the Company also partners with pharmaceutical companies for the use of its core technology in clinical studies.
hi greens! Agreed, was just telling my buddy I am anxious for the medicare approval as I can't even imagine what this will do if/when it gets a million+ in volume.
Nice volume today db7, Looking like this might be the start of an Epic Run up with big news expected soon. Sky is the limit.
DMTK
thanks for sharing that greens; exciting potential!
Yep, see the DMTKW board. G/L!
I spoke with IR today.
The DMTKW warrants expire in 2024.
4 warrants and $23 will get you one share of DMTK.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that company management is scheduled to participate at the following upcoming investor conferences:
John Dobak, M.D., Chief Executive Officer, will be presenting at the Stifel 2019 Healthcare Conference on Wednesday, November 20, 2019 at 8 a.m. Eastern Time at the Lotte New Palace Hotel in New York.
John Dobak, M.D., Chief Executive Officer, will be presenting at the Canaccord Genuity’s 13th Annual Medical Technologies & Diagnostics Forum on Thursday, November 21, 2019 at 1:30 p.m. Eastern Time at the Westin Grand Central in New York.
Good link, I bought more shares this week. When volume picks up on this low floater the stock will fly.
DMTK
DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association
Print
Alert
DermTech (NASDAQ:DMTK)
Intraday Stock Chart
Today : Monday 28 October 2019
Click Here for more DermTech Charts.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the AMA has issued a Proprietary Laboratory Analyses (PLA) Common Procedural Terminology (CPT®) Code for the DermTech Pigmented Lesion Assay. This PLA code was published online with an effective date of July 1, 2019 and is included in the CPT 2020 publication. Medicare rate setting for this proprietary laboratory assay code is currently in process and is expected to be finalized effective for dates of service on or after January 1, 2020.
Burkhard Jansen, M.D., DermTech’s Chief Medical Officer commented, “The receipt of this CPT code is another step toward broadening our contracting and reimbursement success for the Pigmented Lesion Assay.”
DermTech’s Pigmented Lesion Assay uses RT-PCR to measure the gene expression of two genes, LINC00516 (long-intergenic non-coding RNA 00516) and PRAME (preferentially expressed antigen in melanoma) and identifies the malignant changes of melanoma on the genomic level.
About DermTech:
DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the pricing and reimbursement of DermTech’s Pigmented Lesion Assay. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the company; (2) the inability to maintain the listing of the company’s securities on Nasdaq; (3) the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition, the ability of the company to grow and manage growth profitably and retain its key employees; (4) costs related to or resulting from the business combination; (5) changes in applicable laws or regulations; (6) the demand for the company’s services together with the possibility that the company may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties included in (x) the “Risk Factors” sections of the Registration Statement on Form S-4 filed with the SEC by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005279/en/
Sarah Dion
VP Marketing
sdion@dermtech.com
(858) 450-4222
agreed! good luck
Thanks , looking forward to CMS approval, low float should skyrocket on good news.
DMTK
DL38051. If you look at past examples 'most' tend to be 4-5 months from the 'Comment Period End Date' and DMTK's respective date for that event was 6/20/2019.
Based on that, educated guess between 10/20/2019 and 11/20/2019(?)
g/l!
Trying to find it , what ID # is it ? When do expect to hear from CMS ? I bought some shares this week and will be adding more.
DMTK
link to CMS LCD status for DermTech's PLA, looks like determinations are published on Thursdays(?)
https://www.cms.gov/medicare-coverage-database/reports/draft-lcd-status-report.aspx?LCDId=38050&ver=3&name=373*1%7c374*1%7c378*1%7c375*1%7c379*1%7c376*1%7c380*1%7c377*1%7c381*1&bc=AQAAAgAAAAAAResultAnchor
DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its common stock will continue trading on The Nasdaq Capital Market under the symbol “DMTK.” On October 16, 2019, the Nasdaq Hearings Panel (the “Panel”) notified DermTech that it has granted the Company’s request for continued listing of its common stock on The Nasdaq Capital Market because the Company meets all of the requirements for initial listing.
The Panel also determined to delist the Company’s warrants previously trading on The Nasdaq Capital Market under the ticker symbol “DMTKW” (the “Public Warrants”) due to the Company’s failure to demonstrate compliance with Nasdaq Listing Rule 5515(a)(4), which requires the Company to have a minimum of 400 round lot holders of its publicly traded warrants. Accordingly, the Company’s Public Warrants were suspended from The Nasdaq Capital Market effective at the open of trading on October 18, 2019. On the same day, the Public Warrants became available for quotation under the symbol “DMTKW” on the Pink Market operated by OTC Markets Group Inc. Quotes can be found at www.otcmarkets.com.
About DermTech:
DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the Company’s ability to maintain its listing on The Nasdaq Capital Market. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the company; (2) the inability to maintain the listing of the company’s securities on Nasdaq; (3) the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition, the ability of the company to grow and manage growth profitably and retain its key employees; (4) costs related to or resulting from the business combination; (5) changes in applicable laws or regulations; (6) the demand for the company’s services together with the possibility that the company may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties included in (x) the “Risk Factors” sections of the Registration Statement on Form S-4 filed with the SEC by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191018005566/en/
Kevin Sun
investorrelations@dermtech.com
(858) 450-4222
Seems to trade very thin; I love watching it go from under $7 to $7.49 in minutes-
The Company is an emerging growth diagnostics company developing and marketing novel non-invasive gene expression tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. The Company’s technology provides a highly accurate alternative to surgical biopsy, eliminating patient pain, scarring, and risk of infection, while maximizing convenience. The Company’s scalable gene expression assays have been designed to work with a proprietary “adhesive patch biopsy” that provides a tissue sample for analysis non-invasively.
Reverse Merger 8K
https://www.sec.gov/Archives/edgar/data/1651944/000119312519238978/d790602d8k.htm
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
111
|
Created
|
09/11/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |